glp 1 and glp GLP-1-based therapies for type 2 diabetes: from single, dual triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Targeting GLP-1, GIP & GCG

Ghrelin Receptor (GHS-R1a) Selective Activation Ipamorelin acts as a highly selective agonist of the growth hormone secretagogue receptor (GHS-R1a), mimicking the natural hormone ghrelin without affecting other pituitary hormone secretion: Selective binding to GHS-R1a receptors without stimulating ACTH, cortisol, or prolactin release Rapid onset of growth hormone pulse generation (peak levels within 40-60 minutes) No significant effect on appetite stimulation unlike other ghrelin mimetics Preserved feedback regulation through endogenous growth hormone-releasing inhibitory mechanisms Research indicates that ipamorelin releases growth hormone with potency and efficacy similar to GHRP-6 (EC50 approximately 1.3 nmol/L) but with superior selectivity for growth hormone secretion

coli C75

Additionally, according to the Annals of Nutrition & Metabolism, taking creatine may affect glucose homeostasis without changing insulin secretion

There are no adverse interactions between the two supplements, and clinical studies show they are both safe in therapeutic dosages and even tolerated in higher dosages

Medical Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice

31 October 2009